What Actually Changes in Your Second Month on Wegovy

Should you expect the dose to change, and what happens if it does?

The standard Wegovy titration schedule moves from 0.5 mg at weeks five to eight, then to 1.0 mg from week nine onward, with further increases roughly every four weeks after that. For most people, the second month sits squarely across that 0.5 mg to 1.0 mg step. That matters because each dose increase can briefly reintroduce mild gastrointestinal symptoms (nausea, loose stools, or a dull stomach ache) that had already quietened. It is not a sign something has gone wrong; it is the system adjusting again.

Whether to go ahead with an increase, pause at the current dose, or slow the schedule down is a conversation for your prescriber, not a decision to make alone. If the first two weeks were rougher than expected and you opted to stay longer at 0.25 mg, you may still be at 0.5 mg now, that is a reasonable clinical path. The important thing is to keep your prescriber informed rather than managing titration quietly in the background. At nume, a clinical review happens before every repeat order, so this is a natural moment to flag anything that felt off. Your prescriber decides suitability; the schedule in the Patient Information Leaflet is a guide, not a rule you are locked to.

Storage matters more as pens accumulate. Each pen should be refrigerated at 2–8°C between doses; the exact room-temperature window you have if the fridge is unavailable (useful over a long bank holiday or a weekend away) is set out in the Wegovy instructions and in the leaflet inside your pen box. Worth checking rather than guessing.

How much weight loss is realistic by week eight?

This is the question almost everyone has by this point, and the honest answer is that the range is wide. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, but the bulk of that loss did not arrive in a neat straight line. The sharpest drops tended to cluster in months two to four, as doses climbed and the body's appetite signalling changed more substantially.

By the end of month two, many people report losing somewhere between 3% and 6% of their starting weight, though some are further along and others are not yet there. Slower early progress is not predictive of a poor long-term result. What is being treated here is a chronic condition with a biological basis, and biology responds at its own pace. The full picture of how semaglutide works matters more than any single week's number on the scales.

One thing that often surprises people: by the second month, the appetite reduction itself becomes easier to read. The "not hungry" feeling is less unfamiliar and more usable, it becomes possible to eat well rather than just eat less. Protein intake, hydration, and not skipping meals entirely all become more relevant decisions at this stage, because the medicine does the appetite work but does not supply nutrients. If you want a closer look at how people typically feel at this point, reading about the first month on Wegovy can give useful context for how the second month builds on it.

What side effects are most common in the wegovy second month, and when do they need attention?

The gastrointestinal profile of semaglutide (nausea, constipation, diarrhoea, indigestion, bloating) is well characterised, and the NHS medicines page for semaglutide sets it out clearly. In the second month, these effects tend to ease for people who had them early, though a dose increase at week five can temporarily reverse that. Injection-site reactions are possible but uncommon at this stage if the rotation of sites (abdomen, thigh, upper arm) is being kept up.

A small number of people notice mood changes or fatigue in the first few months; this is worth mentioning at the next review. The side effect that warrants prompt medical attention rather than waiting is severe, persistent stomach pain, particularly pain that radiates toward the back, with or without vomiting. This can be a sign of pancreatitis, a known though infrequent risk with GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update and the message is simple: do not sit on that symptom. If it happens, seek medical help the same day. Patients can also report any suspected side effects directly through the Yellow Card scheme.

The more common experience in month two is unremarkable, good weeks and a couple of quieter ones. If a payday lands awkwardly or a holiday falls on your usual order date, it is worth ordering a few days early rather than letting a pen run out mid-cycle. Gaps in treatment are best avoided where possible.

Is this the right time to think about cost and how long treatment continues?

Month two is often the point where the practical and financial questions land in a more concrete way. The early novelty has worn off, the medicine is working, and the question shifts from "will this suit me?" to "can I sustain this?" It is a reasonable moment to revisit what the full course of treatment looks like and what it costs. A plain guide to Wegovy pricing in the UK covers what is typically included and what to watch for, without the hard sell. If you are weighing up the broader landscape of weight-loss treatments, that context can help too.

The clinical consensus, reflected in NICE's guidance on semaglutide (TA875), is that treatment works best alongside sustained lifestyle changes and that stopping early often leads to weight returning. The second month is therefore not just an early milestone, it is a reasonable checkpoint for deciding whether the support around the treatment is strong enough to carry the next six to twelve months. That includes your prescriber relationship, your eating patterns, and your broader health picture. Month three is where many people settle into a genuine rhythm; you can read ahead about what that stage tends to look like on the month three overview.